Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.

American journal of clinical pathology - 1 May 2009

Brunelli Matteo, Manfrin Erminia, Martignoni Guido, Miller Keith, Remo Andrea, Reghellin Daniela, Bersani Samantha, Gobbo Stefano, Eccher Albino, Chilosi Marco, Bonetti Franco

Abstract excerpt

We evaluated intratumoral heterogeneity of 30 ductal breast carcinomas with HER2/neu amplification, scored by the American Society of Clinical Oncology/ College of American Pathologists (ASCO/CAP) criteria, and 3+ immunoexpression. High-grade (ratio > or =4.0) vs low-grade amplification (ratio >2.2 to <4.0) and chromosome 17 polysomy were also evaluated. On whole tissue sections, 20 tumors (67%) showed high-grade...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Ductal, Breast
Share to Chromosomes, Human, Pair 17

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Amplification

Share to Genes, erbB-2

Share to Genetic Heterogeneity

Share to Practice Guidelines as Topic

Share to Receptor, ErbB-2

Share to Societies, Medical

Source

Identifiers

PMID: 19369627
DOI: 10.1309/AJCP09VUTZWZXBMJ

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification: evaluation according to ASCO/CAP criteria.PMID 19369627Read ↗

<i>HER2</i> genetic heterogeneity in breast carcinomaSemantic proximity Read ↗

Genetic Heterogeneity in HER2 Testing in Breast Cancer: Panel Summary and GuidelinesSemantic proximity Read ↗

Frequency of HER2 Heterogeneity by Fluorescence In Situ Hybridization According to CAP Expert Panel RecommendationsSemantic proximity Read ↗

Tumor Heterogeneity in Breast CancerSemantic proximity Read ↗

High HER2 intratumoral heterogeneity is a predictive factor for poor prognosis in Early-stage and Locally Advanced HER2-positive Breast CancerSemantic proximity Read ↗

Intratumoral Heterogeneity of HER2/neu in Breast Cancer?A Rare EventSemantic proximity Read ↗

Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification.Semantic proximity Read ↗

Intratumor heterogeneity defines treatment‐resistant HER 2+ breast tumorsSemantic proximity Read ↗

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.Semantic proximity Read ↗

Intratumoral Heterogeneity of HER-2/neu in Invasive Mammary Carcinomas Using Fluorescence In-Situ Hybridization and Tissue MicroarraySemantic proximity Read ↗

Intra-tumor heterogeneity defines treatment-resistant HER2+ breast tumorsSemantic proximity Read ↗

Breast cancer complexity: implications of intratumoral heterogeneity in clinical managementSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.